Articles & Issues
- Language
- English
- Conflict of Interest
- In relation to this article, we declare that there is no conflict of interest.
- Publication history
-
Received April 24, 2014
Accepted August 4, 2014
-
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/bync/3.0) which permits
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright © KIChE. All rights reserved.
All issues
Investigation on the role of ion exchange resin in the crystallization process for the purification of vancomycin
Department of Chemical Engineering, Kongju National University, Cheonan 330-717, Korea
Korean Journal of Chemical Engineering, March 2015, 32(3), 465-470(6), 10.1007/s11814-014-0222-0
Download PDF
Abstract
We investigated the cause of a difference in the crystallization aspect depending on a surface area-increasing material (ion exchange resin) in the vancomycin crystallization process with increased surface area per volume of reaction solution (S/V). The result in terms of whether or not crystallization occurred was reversed when the ionic form of the ion exchange resin was altered. In addition, it was shown that the pH range of a solution for vancomycin crystallization was 4-7. Eventually, it was confirmed that vancomycin crystallization was affected by a change in pH of a crystallization solution depending on the ionic form of the ion exchange resin. Furthermore, in the absence of ion exchange resin, the time required for crystallization increased as the pH rose from 4-7. In addition, the size of the vancomycin crystal increased as the pH decreased.
References
Yan H, Qi D, Cheng X, Song Z, Li W, He B, J. Antibiot., 51, 750 (1998)
Griffith RS, J. Antimicrob. Chemother., 14, 1 (1984)
Kim SI, Han CY, Jung HS, Lee JS, Ok SY, Kim SC, Korean J. Anesthesiol., 51, 727 (2006)
United States Pharmacopoeia (USP 29): Vancomycin hydrochloride, United State Pharmacopeial Convention, Inc. (2006)
Javadzadeh Y, Mohammadi A, Khoei N, Nokhodchi A, Acta Pharm., 59, 187 (2009)
Kim SI, Jeong KE, Jeong SY, Kim CU, J. Korean Oil Chem. Soc., 25, 232 (2008)
Kim WS, Lee EK, Korean J. Biotechnol. Bioeng., 20, 164 (2005)
Kim KJ, Prospect. Ind. Chem., 4(4), 1 (2001)
Lee JY, Lee KH, Chae HJ, Kim JH, Korean J. Chem. Eng., 27(5), 1538 (2010)
Kim YN, Lee JY, Kim JH, Process Biochem., 46, 2068 (2011)
Kwak EA, Kim SJ, Kim JH, Korean J. Chem. Eng., 29(11), 1487 (2012)
Lee JW, Jung YT, Suh JW, Lee KS, US Patent, 7,018,814 (2006)
U. S. Food and Drug Administration: Vancomycin solubility study, Report to office of generic drugs; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm082291.pdf (2008)
Claudius JS, Neau SH, Int. J. Pharm., 168, 41 (1998)
Griffith RS, J. Antimicrob. Chemother., 14, 1 (1984)
Kim SI, Han CY, Jung HS, Lee JS, Ok SY, Kim SC, Korean J. Anesthesiol., 51, 727 (2006)
United States Pharmacopoeia (USP 29): Vancomycin hydrochloride, United State Pharmacopeial Convention, Inc. (2006)
Javadzadeh Y, Mohammadi A, Khoei N, Nokhodchi A, Acta Pharm., 59, 187 (2009)
Kim SI, Jeong KE, Jeong SY, Kim CU, J. Korean Oil Chem. Soc., 25, 232 (2008)
Kim WS, Lee EK, Korean J. Biotechnol. Bioeng., 20, 164 (2005)
Kim KJ, Prospect. Ind. Chem., 4(4), 1 (2001)
Lee JY, Lee KH, Chae HJ, Kim JH, Korean J. Chem. Eng., 27(5), 1538 (2010)
Kim YN, Lee JY, Kim JH, Process Biochem., 46, 2068 (2011)
Kwak EA, Kim SJ, Kim JH, Korean J. Chem. Eng., 29(11), 1487 (2012)
Lee JW, Jung YT, Suh JW, Lee KS, US Patent, 7,018,814 (2006)
U. S. Food and Drug Administration: Vancomycin solubility study, Report to office of generic drugs; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm082291.pdf (2008)
Claudius JS, Neau SH, Int. J. Pharm., 168, 41 (1998)
